AAPL299.23+1.22 (+0.41%) ▲|ABBV229.90+13.41 (+6.19%) ▲|ABT88.22-0.19 (-0.21%) ▼|ACN119.17-8.82 (-6.89%) ▼|ADBE192.21-2.95 (-1.51%) ▼|AMAT622.55+5.44 (+0.88%) ▲|AMD545.39+8.02 (+1.49%) ▲|AMGN343.49+5.89 (+1.74%) ▲|AMT176.87+0.82 (+0.47%) ▲|AMZN234.41-9.99 (-4.09%) ▼|AVGO394.63-16.72 (-4.06%) ▼|AXP336.49-1.51 (-0.45%) ▼|BA220.85-1.87 (-0.84%) ▼|BAC57.32+1.12 (+1.98%) ▲|BKNG167.98-3.80 (-2.21%) ▼|BLK1,046.72-3.38 (-0.32%) ▼|BMY54.41+0.41 (+0.75%) ▲|BNY145.86+2.23 (+1.55%) ▲|BRK-B489.03-0.43 (-0.09%) ▼|C145.35+2.29 (+1.60%) ▲|CAT1,017.74+31.92 (+3.24%) ▲|CL89.69+0.21 (+0.23%) ▲|CMCSA22.40-0.04 (-0.16%) ▼|COF200.90-0.64 (-0.32%) ▼|COP109.38+1.64 (+1.52%) ▲|COST948.42-3.03 (-0.32%) ▼|CRM149.11-2.67 (-1.76%) ▼|CSCO121.19+1.65 (+1.38%) ▲|CVS101.85+3.53 (+3.59%) ▲|CVX175.00+1.37 (+0.79%) ▲|DE596.83+7.59 (+1.29%) ▲|DHR177.81+0.64 (+0.36%) ▲|DIS101.91-1.99 (-1.91%) ▼|DUK124.26+0.40 (+0.32%) ▲|EMR149.71-0.95 (-0.63%) ▼|FDX327.69+2.71 (+0.83%) ▲|GD343.06-6.95 (-1.99%) ▼|GE357.43-0.21 (-0.06%) ▼|GEV1,126.04+16.31 (+1.47%) ▲|GILD124.53+0.77 (+0.62%) ▲|GM80.88+1.59 (+2.01%) ▲|GOOG347.18-20.28 (-5.52%) ▼|GOOGL347.82-20.21 (-5.49%) ▼|GS1,098.72+2.16 (+0.20%) ▲|HD326.72-7.56 (-2.26%) ▼|HON228.36-0.66 (-0.29%) ▼|IBM246.50-2.60 (-1.04%) ▼|INTC140.81+6.82 (+5.09%) ▲|INTU256.53-10.47 (-3.92%) ▼|ISRG401.95-4.83 (-1.19%) ▼|JNJ230.40+2.01 (+0.88%) ▲|JPM331.90+6.68 (+2.05%) ▲|KO79.84+0.45 (+0.57%) ▲|LIN514.18+2.03 (+0.40%) ▲|LLY1,104.38+5.81 (+0.53%) ▲|LMT492.33-18.62 (-3.64%) ▼|LOW214.13-8.07 (-3.63%) ▼|LRCX395.18+6.14 (+1.58%) ▲|MA483.72-6.07 (-1.24%) ▼|MCD270.80-7.82 (-2.81%) ▼|MDLZ59.85-0.27 (-0.45%) ▼|MDT79.17-0.17 (-0.21%) ▼|META565.20-12.02 (-2.08%) ▼|MMM162.45+1.85 (+1.15%) ▲|MO69.65+0.53 (+0.76%) ▲|MRK114.75+0.88 (+0.77%) ▲|MS227.19+4.02 (+1.80%) ▲|MSFT370.13-9.27 (-2.44%) ▼|MU1,194.66+60.67 (+5.35%) ▲|NEE86.60-0.16 (-0.18%) ▼|NFLX72.86-4.52 (-5.84%) ▼|NKE43.21-2.00 (-4.41%) ▼|NOW92.05-2.99 (-3.15%) ▼|NVDA208.65-2.04 (-0.97%) ▼|ORCL175.26-9.04 (-4.90%) ▼|PEP140.70-1.33 (-0.93%) ▼|PFE25.01-0.21 (-0.81%) ▼|PG148.80-1.58 (-1.05%) ▼|PLTR119.62-8.86 (-6.89%) ▼|PM173.53-4.87 (-2.73%) ▼|QCOM222.21-3.90 (-1.72%) ▼|RTX182.46-3.14 (-1.69%) ▼|SBUX100.00-0.65 (-0.65%) ▼|SCHW92.03+0.33 (+0.35%) ▲|SO93.86+0.77 (+0.82%) ▲|SPG213.67+2.34 (+1.11%) ▲|T22.17+0.16 (+0.70%) ▲|TMO461.89-2.72 (-0.59%) ▼|TMUS181.05-0.62 (-0.34%) ▼|TSLA405.86+5.37 (+1.34%) ▲|TXN328.55+5.69 (+1.76%) ▲|UBER71.74+0.10 (+0.14%) ▲|UNH408.36+7.40 (+1.84%) ▲|UNP259.79+2.91 (+1.13%) ▲|UPS107.50+2.64 (+2.52%) ▲|USB58.58+0.44 (+0.75%) ▲|V326.67-0.57 (-0.17%) ▼|VZ45.41+0.04 (+0.09%) ▲|WFC83.81+1.61 (+1.95%) ▲|WMT117.20+0.02 (+0.02%) ▲|XOM138.48+0.67 (+0.49%) ▲|AAPL299.23+1.22 (+0.41%) ▲|ABBV229.90+13.41 (+6.19%) ▲|ABT88.22-0.19 (-0.21%) ▼|ACN119.17-8.82 (-6.89%) ▼|ADBE192.21-2.95 (-1.51%) ▼|AMAT622.55+5.44 (+0.88%) ▲|AMD545.39+8.02 (+1.49%) ▲|AMGN343.49+5.89 (+1.74%) ▲|AMT176.87+0.82 (+0.47%) ▲|AMZN234.41-9.99 (-4.09%) ▼|AVGO394.63-16.72 (-4.06%) ▼|AXP336.49-1.51 (-0.45%) ▼|BA220.85-1.87 (-0.84%) ▼|BAC57.32+1.12 (+1.98%) ▲|BKNG167.98-3.80 (-2.21%) ▼|BLK1,046.72-3.38 (-0.32%) ▼|BMY54.41+0.41 (+0.75%) ▲|BNY145.86+2.23 (+1.55%) ▲|BRK-B489.03-0.43 (-0.09%) ▼|C145.35+2.29 (+1.60%) ▲|CAT1,017.74+31.92 (+3.24%) ▲|CL89.69+0.21 (+0.23%) ▲|CMCSA22.40-0.04 (-0.16%) ▼|COF200.90-0.64 (-0.32%) ▼|COP109.38+1.64 (+1.52%) ▲|COST948.42-3.03 (-0.32%) ▼|CRM149.11-2.67 (-1.76%) ▼|CSCO121.19+1.65 (+1.38%) ▲|CVS101.85+3.53 (+3.59%) ▲|CVX175.00+1.37 (+0.79%) ▲|DE596.83+7.59 (+1.29%) ▲|DHR177.81+0.64 (+0.36%) ▲|DIS101.91-1.99 (-1.91%) ▼|DUK124.26+0.40 (+0.32%) ▲|EMR149.71-0.95 (-0.63%) ▼|FDX327.69+2.71 (+0.83%) ▲|GD343.06-6.95 (-1.99%) ▼|GE357.43-0.21 (-0.06%) ▼|GEV1,126.04+16.31 (+1.47%) ▲|GILD124.53+0.77 (+0.62%) ▲|GM80.88+1.59 (+2.01%) ▲|GOOG347.18-20.28 (-5.52%) ▼|GOOGL347.82-20.21 (-5.49%) ▼|GS1,098.72+2.16 (+0.20%) ▲|HD326.72-7.56 (-2.26%) ▼|HON228.36-0.66 (-0.29%) ▼|IBM246.50-2.60 (-1.04%) ▼|INTC140.81+6.82 (+5.09%) ▲|INTU256.53-10.47 (-3.92%) ▼|ISRG401.95-4.83 (-1.19%) ▼|JNJ230.40+2.01 (+0.88%) ▲|JPM331.90+6.68 (+2.05%) ▲|KO79.84+0.45 (+0.57%) ▲|LIN514.18+2.03 (+0.40%) ▲|LLY1,104.38+5.81 (+0.53%) ▲|LMT492.33-18.62 (-3.64%) ▼|LOW214.13-8.07 (-3.63%) ▼|LRCX395.18+6.14 (+1.58%) ▲|MA483.72-6.07 (-1.24%) ▼|MCD270.80-7.82 (-2.81%) ▼|MDLZ59.85-0.27 (-0.45%) ▼|MDT79.17-0.17 (-0.21%) ▼|META565.20-12.02 (-2.08%) ▼|MMM162.45+1.85 (+1.15%) ▲|MO69.65+0.53 (+0.76%) ▲|MRK114.75+0.88 (+0.77%) ▲|MS227.19+4.02 (+1.80%) ▲|MSFT370.13-9.27 (-2.44%) ▼|MU1,194.66+60.67 (+5.35%) ▲|NEE86.60-0.16 (-0.18%) ▼|NFLX72.86-4.52 (-5.84%) ▼|NKE43.21-2.00 (-4.41%) ▼|NOW92.05-2.99 (-3.15%) ▼|NVDA208.65-2.04 (-0.97%) ▼|ORCL175.26-9.04 (-4.90%) ▼|PEP140.70-1.33 (-0.93%) ▼|PFE25.01-0.21 (-0.81%) ▼|PG148.80-1.58 (-1.05%) ▼|PLTR119.62-8.86 (-6.89%) ▼|PM173.53-4.87 (-2.73%) ▼|QCOM222.21-3.90 (-1.72%) ▼|RTX182.46-3.14 (-1.69%) ▼|SBUX100.00-0.65 (-0.65%) ▼|SCHW92.03+0.33 (+0.35%) ▲|SO93.86+0.77 (+0.82%) ▲|SPG213.67+2.34 (+1.11%) ▲|T22.17+0.16 (+0.70%) ▲|TMO461.89-2.72 (-0.59%) ▼|TMUS181.05-0.62 (-0.34%) ▼|TSLA405.86+5.37 (+1.34%) ▲|TXN328.55+5.69 (+1.76%) ▲|UBER71.74+0.10 (+0.14%) ▲|UNH408.36+7.40 (+1.84%) ▲|UNP259.79+2.91 (+1.13%) ▲|UPS107.50+2.64 (+2.52%) ▲|USB58.58+0.44 (+0.75%) ▲|V326.67-0.57 (-0.17%) ▼|VZ45.41+0.04 (+0.09%) ▲|WFC83.81+1.61 (+1.95%) ▲|WMT117.20+0.02 (+0.02%) ▲|XOM138.48+0.67 (+0.49%) ▲|
21 C
New York
Monday, June 22, 2026

Tag: cells

Desay Battery Showcases Full-Stack Energy Storage Solutions at Battery Expo 2025 in Vietnam

HUIZHOU, China, June 27, 2025 /PRNewswire/ -- Desay Battery, a leading global provider of comprehensive energy storage solutions, took the stage at Battery Expo...

Desay Battery Showcases Full-Stack Energy Storage Solutions at Battery Expo 2025 in Vietnam

HUIZHOU, China, June 27, 2025 /PRNewswire/ -- Desay Battery, a leading global provider of comprehensive energy storage solutions, took the stage at Battery Expo...

Challenge accepted: New funding for ambitious projects within biomanufacturing, cardiometabolic diseases, and artificial intelligence

The 2025 Novo Nordisk Foundation Challenge Programme awards DKK 479 million to nine innovative projects that advance health and sustainability through cooperation between researchers from...

„EPSO-G“ įmonių grupei „Moody‘s Ratings“ patvirtino kredito reitingą Baa1

Naujosios energetikos įmonių grupė „EPSO-G“ (toliau – Grupė) (įmonės kodas 302826889, registruotos buveinės adresas Laisvės pr. 10, Vilnius, Lietuva)

Moody’s Ratings affirms Baa1 credit rating for EPSO-G Group

EPSO-G (legal entity code 302826889, registered address Laisvės pr. 10, Vilnius, Lithuania)

Challenge accepted: New funding for ambitious projects within biomanufacturing, cardiometabolic diseases, and artificial intelligence

The 2025 Novo Nordisk Foundation Challenge Programme awards DKK 479 million to nine innovative projects that advance health and sustainability through cooperation between researchers from...

MGI ANNOUNCES PARTNERSHIP WITH NEGEDIA: ENHANCE GENOMIC SEQUENCING TECHNOLOGIES AT THE SERVICE OF SCIENTIFIC RESEARCH AND PRECISION MEDICINE IN ITALY

In the study of rare diseases and precision medicine, understanding gene expression in the spatial context of tissues is essential. High-throughput sequencing and STOmics technology will...

Anti-CCR8 Antibodies Market to Witness Remarkable Growth Trajectory During the Forecast Period (2025-2040) Across 7MM | DelveInsight

The anti-CCR8 antibodies market holds potential in addressing unmet needs across inflammatory and cancerous diseases. The anti-CCR8 inhibitor market is expected to witness substantial...

Anti-CCR8 Antibodies Market to Witness Remarkable Growth Trajectory During the Forecast Period (2025-2040) Across 7MM | DelveInsight

The anti-CCR8 antibodies market holds potential in addressing unmet needs across inflammatory and cancerous diseases. The anti-CCR8 inhibitor market is expected to witness substantial...

ProQR Announces CTA Submission for Phase 1 Study of AX-0810 Targeting NTCP

LEIDEN, Netherlands & CAMBRIDGE, Mass., June 26, 2025 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer™ RNA editing technology platform, today announced the submission of a Clinical Trial Application (CTA) to the European Medicines Agency (EMA) to initiate a Phase 1 clinical trial of its lead pipeline program AX-0810 targeting NTCP, a liver cell protein that transports bile acids into cells. AX-0810 is an investigational ADAR-mediated RNA editing oligonucleotide (EON) designed to selectively modulate NTCP function by reducing toxic bile acid accumulation in the liver, potentially mitigating inflammation, fibrosis, and progression toward liver failure, which are common in cholestatic diseases.

Food-Derived Longevity Supplement Primeadine® GF Launches at Erewhon

Primeadine® GF, Oxford Healthspan’s gluten-free spermidine supplement, is now available at all 10 Erewhon locations across Southern California.

Photovoltaics Market worth $968.32 billion by 2030 – Exclusive Report by MarketsandMarkets™

DELRAY BEACH, Fla., June 26, 2025 /PRNewswire/ -- The global photovoltaics market is projected to reach USD 968.32 billion by 2030 from USD 613.57 billion...

Photovoltaics Market worth $968.32 billion by 2030 – Exclusive Report by MarketsandMarkets™

DELRAY BEACH, Fla., June 26, 2025 /PRNewswire/ -- The global photovoltaics market is projected to reach USD 968.32 billion by 2030 from USD 613.57 billion...

STORM Therapeutics Appoints Veteran Cancer Drug Developer Dr. Eric Martin as Chief Development Officer

CAMBRIDGE, England, June 26, 2025 /PRNewswire/ -- STORM Therapeutics Ltd. (STORM), the clinical stage company pioneering cellular reprogramming through RNA modifications to treat disease, today...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsCells